Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer U.S. Focus Will Be Oncology, Blood Products And OTCs

Executive Summary

Bayer will focus its U.S. pharmaceutical operations on OTCs, oncology and blood products following an agreement giving Schering-Plough marketing rights to its primary care brands

You may also be interested in...



Bayer/Schering’s Complementary Portfolios Include Focus On Oncology

Bayer does not expect to divest any pharmaceutical products following the acquisition of Schering AG, CEO Werner Wenning said March 24 during a briefing outlining the planned merger

Bayer/Schering’s Complementary Portfolios Include Focus On Oncology

Bayer does not expect to divest any pharmaceutical products following the acquisition of Schering AG, CEO Werner Wenning said March 24 during a briefing outlining the planned merger

Bayer Nexavar Safety Profile Fuels Research In Multiple Cancer Indications

A dual mode of action and favorable safety profile will be the chief selling points for Bayer/Onyx' kidney cancer agent Nexavar (sorafenib), company officials said during Bayer's R&D investor conference in London Dec. 8

Related Content

Topics

UsernamePublicRestriction

Register

PS044667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel